Moleculin’s Annamycin Cardiac Safety Data to Debut at 2026 ASCO Meeting — Moleculin Biotech, Inc.

Event summary

Moleculin’s abstract on annamycin’s cardiac safety accepted for poster presentation at 2026 ASCO Annual Meeting (May 30, 2026).
Data focuses on cardiac safety of annamycin in patients with high cumulative anthracycline exposure.
ASCO meeting runs May 29–June 2, 2026, in Chicago.
Annamycin is Moleculin’s lead drug candidate for relapsed/refractory AML and soft tissue sarcoma lung metastases.

The big picture

Moleculin’s ASCO presentation underscores the strategic importance of cardiac safety in anthracycline development, a critical differentiator in oncology. The data could bolster annamycin’s standing as a next-generation therapy, particularly in relapsed/refractory AML, where cardiotoxicity remains a major limitation. The ASCO platform provides Moleculin with high-visibility validation ahead of pivotal trial milestones.

What we're watching

Clinical Validation: Whether ASCO presentation accelerates annamycin’s profile as a differentiated anthracycline.
Regulatory Pathway: The pace at which Moleculin advances the MIRACLE trial for AML approval.
Market Differentiation: How cardiac safety data impacts annamycin’s competitive positioning against existing anthracyclines.